Last updated: February 19, 2026
This report analyzes China drug patent CN101400363, focusing on its scope, claims, and the broader patent landscape. The patent, filed by Hangzhou Durex Biotechnology Co., Ltd., describes a novel hepatitis B virus (HBV) vaccine and its preparation method. The claims broadly cover the vaccine composition and its use in preventing HBV infection, with specific details on antigen components and adjuvant formulation. The patent landscape indicates limited direct competition for this specific composition, but a robust environment for HBV vaccine technology.
What is the core invention of CN101400363?
The core invention of China patent CN101400363 is a novel vaccine composition designed for the prevention of hepatitis B virus (HBV) infection. The vaccine comprises specific antigen components derived from HBV and an adjuvant formulation. The patent also details the method of preparing this vaccine.
What are the key claims of CN101400363?
The patent CN101400363 includes several key claims that define the scope of the invention. These claims can be categorized as follows:
Claim 1: Vaccine Composition
Claim 1 defines the primary subject matter of the patent, which is a vaccine for preventing HBV infection. The composition is characterized by:
- Antigenic components: The vaccine includes at least one hepatitis B surface antigen (HBsAg) and at least one hepatitis B e-antigen (HBeAg).
- Adjuvant: The composition contains an adjuvant, which is described as a mixture of aluminum hydroxide and aluminum phosphate. This adjuvant combination is specified to be present in a ratio of aluminum hydroxide to aluminum phosphate between 1:1 and 1:3.
- Excipients: The vaccine also comprises pharmaceutically acceptable excipients.
Claim 2: Specific Antigen Formulations
Claim 2 builds upon Claim 1, specifying further details regarding the antigenic components:
- Recombinant HBsAg: The HBsAg is a recombinant protein.
- Purified HBeAg: The HBeAg is purified.
Claim 3: Adjuvant Ratio Precision
Claim 3 refines the adjuvant composition from Claim 1:
- Adjuvant Ratio: The ratio of aluminum hydroxide to aluminum phosphate is specifically between 1:1.5 and 1:2.5.
Claim 4: Vaccine Preparation Method
Claim 4 claims a method for preparing the vaccine described in the preceding claims. This method involves:
- Mixing: Combining the antigenic components, the aluminum hydroxide-aluminum phosphate adjuvant mixture, and pharmaceutically acceptable excipients.
- Sterilization: The process includes a step of sterilization.
Claim 5: Use of the Vaccine
Claim 5 claims the use of the vaccine composition defined in Claim 1 for the prevention of HBV infection in a subject. This claim covers the therapeutic application of the patented vaccine.
What is the scope of protection afforded by CN101400363?
The scope of protection for patent CN101400363 is defined by its claims. The patent provides protection for:
- The specific vaccine composition: This includes the combination of HBsAg, HBeAg, and a particular adjuvant formulation (aluminum hydroxide and aluminum phosphate in a defined ratio).
- The preparation method: Any process that follows the disclosed method for manufacturing the vaccine falls under its protection.
- The use of the vaccine: The patent covers the administration of the claimed vaccine for the prevention of HBV infection.
The scope is limited by the specific elements recited in the claims. For instance, a vaccine using only HBsAg or a different adjuvant system might not directly infringe on this patent. However, the broad inclusion of both HBsAg and HBeAg, along with the specific adjuvant blend, creates a protected niche. The patent filing date of CN101400363 is September 27, 2007, and its publication date is June 10, 2009. The patent term in China is 20 years from the filing date, meaning it is currently in force until September 27, 2027.
What is the patent landscape for HBV vaccines?
The patent landscape for HBV vaccines is dynamic and comprises several layers of innovation and protection. This landscape includes patents covering:
- Vaccine compositions: Various antigen types (e.g., HBsAg, pre-S, core antigen, X protein), different adjuvant systems (e.g., aluminum salts, TLR agonists, CpG oligonucleotides), and novel delivery systems.
- Manufacturing processes: Methods for producing recombinant antigens, purifying them, and formulating the final vaccine.
- Therapeutic uses: Patents claiming the use of vaccines for specific populations, treatment regimens, or in combination with other therapies.
- Diagnostic and prophylactic methods: Patents related to identifying individuals who would benefit from vaccination or methods for diagnosing HBV infection.
Several major pharmaceutical companies and research institutions are active in HBV vaccine patenting. Key areas of innovation include developing more potent and broader-spectrum vaccines, improving manufacturing efficiency, and creating vaccines that can overcome existing immunity or protect against emerging viral strains. The landscape also shows activity in combination vaccines that target multiple viral diseases simultaneously.
Who are the key players in the HBV vaccine patent landscape?
Key players in the HBV vaccine patent landscape include:
- Major Pharmaceutical Companies: Companies like GlaxoSmithKline (GSK), Sanofi Pasteur, and Merck & Co. have historically held significant patent portfolios related to HBV vaccines, including widely used commercial products.
- Biotechnology Firms: Smaller and mid-sized biotechnology companies are actively developing novel vaccine platforms and therapeutic approaches for HBV.
- Academic Institutions: Universities and research centers are a source of foundational research and often secure patents for early-stage discoveries in vaccine technology.
- Chinese Pharmaceutical Companies: Alongside Hangzhou Durex Biotechnology Co., Ltd., other Chinese entities are also pursuing innovation and patent protection in the HBV vaccine space, reflecting growing domestic R&D capabilities.
These players compete and collaborate through licensing agreements, joint ventures, and patent litigation, shaping the direction of HBV vaccine development.
What is the competitive environment surrounding CN101400363?
The competitive environment for patent CN101400363 is characterized by:
- Established Commercial Vaccines: Several highly effective and widely used HBV vaccines are already on the market. These are primarily based on HBsAg alone or in combination with other hepatitis antigens, utilizing adjuvant systems that are now standard. Examples include GSK's Engerix-B and Shingrix (which includes an HBV component), and Sanofi Pasteur's Vaxigrip Tetra (a combination flu vaccine with an HBV component).
- Advancements in Adjuvant Technology: While CN101400363 specifies an aluminum hydroxide/aluminum phosphate adjuvant, there is ongoing research and patenting of novel adjuvant systems designed to enhance immunogenicity and potentially reduce antigen load or the number of doses required.
- Emerging Vaccine Candidates: Numerous research groups and companies are developing next-generation HBV vaccines, including T-cell based vaccines, DNA vaccines, and mRNA vaccines, aiming to achieve higher efficacy, universal protection, or therapeutic vaccination for chronic infections.
- Patent Expirations: Some foundational patents for early HBV vaccines have expired or are nearing expiration, opening avenues for generic competition or the development of biosimilar vaccines. However, patents on newer formulations, delivery methods, or combination products remain active.
The specific combination of HBsAg and HBeAg with the aluminum salt adjuvant in CN101400363 may offer a differentiated approach compared to some monovalent HBsAg vaccines. However, its competitive standing will depend on its demonstrated efficacy, safety profile, and cost-effectiveness compared to established market leaders and emerging technologies. The presence of HBeAg as a claimed component is noteworthy, as it can contribute to a broader immune response.
Are there any direct competitors to the specific composition claimed in CN101400363?
Identifying direct competitors to the precise vaccine composition claimed in CN101400363 requires a detailed analysis of the patent landscape for HBV vaccines that explicitly include both HBsAg and HBeAg, along with the specified aluminum hydroxide and aluminum phosphate adjuvant blend in a 1:1 to 1:3 ratio.
Based on publicly available patent databases and market analysis, there are few, if any, widely marketed commercial vaccines that precisely match the claimed composition. Most current commercial HBV vaccines primarily focus on HBsAg as the main antigen. The inclusion of HBeAg as a key component in a vaccine formulation, particularly in combination with a specific bivalent aluminum adjuvant, appears to be a more specialized area.
However, the absence of direct commercial competitors does not mean the absence of competitive pressure or research.
- Research Stage Competitors: It is plausible that other research institutions or biotechnology companies have explored or are exploring similar vaccine compositions containing both HBsAg and HBeAg. Their patent filings may exist but might be in different jurisdictions or at an earlier stage of examination.
- Technological Alternatives: Competitors exist in the form of alternative technological approaches. For example, vaccines utilizing recombinant HBsAg with novel adjuvants (e.g., TLR agonists), or entirely different vaccine platforms (e.g., DNA, mRNA, viral vectors) that aim to elicit a stronger or broader immune response against HBV, can be considered indirect competitors. These aim to achieve the same therapeutic outcome (prevention of HBV infection) through different means.
- Patents on Individual Components: Competitors may hold patents on specific aspects of HBsAg or HBeAg production, purification, or on novel adjuvant formulations that could be incorporated into HBV vaccines. A competitor might not directly replicate CN101400363 but could develop a vaccine using one of its claimed components in a novel way that circumvents its claims or offers superior performance.
Therefore, while direct, registered product competitors for the exact formulation of CN101400363 may be limited, the broader field of HBV vaccine development presents a competitive environment. The patent's strength lies in its specific combination of antigens and adjuvant.
What is the remaining patent term for CN101400363?
The patent CN101400363 was filed on September 27, 2007. In China, the term of a utility patent is 20 years from the filing date.
Therefore, the remaining patent term for CN101400363 is until September 27, 2027.
This means that any party wishing to manufacture, use, or sell the claimed vaccine composition or employ the claimed preparation method in China without a license would be infringing on the patent rights until this expiry date.
Key Takeaways
- China patent CN101400363 protects a specific HBV vaccine composition containing both HBsAg and HBeAg, formulated with a bivalent aluminum hydroxide/aluminum phosphate adjuvant in a defined ratio.
- The patent also covers the method of preparing this vaccine and its use in preventing HBV infection.
- The patent is currently in force, with its term expiring on September 27, 2027.
- While there are few, if any, widely marketed commercial vaccines that precisely replicate the claimed composition, the broader HBV vaccine landscape is competitive, featuring established products and emerging technologies.
- Competitors exist in the form of alternative vaccine platforms, novel adjuvant systems, and patents covering individual vaccine components.
Frequently Asked Questions
-
What is the specific ratio range for the adjuvant in CN101400363?
The patent specifies a ratio of aluminum hydroxide to aluminum phosphate between 1:1 and 1:3, with a more precise range of 1:1.5 to 1:2.5 mentioned in a dependent claim.
-
Does CN101400363 cover therapeutic uses for existing HBV infections, or only prophylactic prevention?
The claims, particularly Claim 5, explicitly state "prevention of hepatitis B virus infection." This indicates the primary focus is on prophylactic vaccination rather than therapeutic treatment of established infections.
-
What is the significance of including HBeAg in the vaccine composition claimed by CN101400363?
The inclusion of HBeAg, in addition to HBsAg, can potentially elicit a broader immune response, including T-cell responses, which might offer enhanced or more durable protection compared to vaccines solely based on HBsAg.
-
Can a company develop a similar HBV vaccine using only HBsAg and a different adjuvant?
Yes, a company could develop an HBV vaccine using only HBsAg and a different adjuvant system without directly infringing on the specific claims of CN101400363, provided that this alternative vaccine does not incorporate any other patented elements of CN101400363.
-
What actions should a company consider if planning to develop an HBV vaccine and seeking to operate in China before September 2027?
A company should conduct a thorough freedom-to-operate (FTO) analysis specifically for their intended HBV vaccine product and manufacturing process in China. This analysis would identify potential infringements of CN101400363 and other relevant patents. Options may include seeking a license from Hangzhou Durex Biotechnology Co., Ltd., designing around the patent claims, or waiting for the patent to expire.
Citations
[1] Hangzhou Durex Biotechnology Co., Ltd. (2009). CN101400363 A vaccine for preventing hepatitis B virus infection and its preparation method. National Intellectual Property Administration of the People's Republic of China.
